Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 28, Issue 2, Pages 231-239Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1185/03007995.2011.648758
Keywords
DMOAD; Joint space width; Knee osteoarthritis; Knee radiograph; Randomized clinical trial; Strontium ranelate; Structure-modifying treatment
Funding
- Servier, France
- Executive Committee
- Amgen
- ABBH
- Novartis
- Pfizer
- Eli Lilly
- Servier
- Negma
- Lilly
- Wyeth
- GlaxoSmithKline
- Roche
- Merckle
- Nycomed
- NPS
- Theramex
- UCB
- Rottapharm
- IBSA
- Genevrier
- Teijin
- Teva
- Ebewee Pharma
- Zodiac
- Analis
- Novo-Nordisk
- Bristol Myers Squibb
- Merck
- Novo Nordisk
- Groupe Fournier
- Proctor and Gamble
- Besins EscoVesco
- Merck Sharp and Dohme
- Chiesi
- Boehringer Mannheim
- Genentech
- ONO
- Abbott
- Janssen
- Merck-Schering
- Warner Chilcott
- Fidia
- Pierre Fabre
- Smith Nephews
- Expanscience
- Genzyme
- Medical Research Council [MC_UP_A620_1014, U1475000001] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10082] Funding Source: researchfish
Ask authors/readers for more resources
Objective: The osteoporosis drug strontium ranelate dissociates bone remodelling processes. It also inhibits subchondral bone resorption and stimulates cartilage matrix formation in vitro. Exploratory studies in the osteoporosis trials report that strontium ranelate reduces biomarkers of cartilage degradation, and attenuates the progression and clinical symptoms of spinal osteoarthritis, suggesting symptom-and structure-modifying activity in osteoarthritis. We describe the rationale and design of a randomised trial evaluating the efficacy and safety of strontium ranelate in knee osteoarthritis. Research design, methods, and results: This double-blind, placebo-controlled trial (98 centres, 18 countries) includes ambulatory Caucasian men and women aged >= 50 years with primary knee osteoarthritis of the medial tibiofemoral compartment (Kellgren and Lawrence grade 2 or 3), joint space width (JSW) 2.5 to 5 mm, and knee pain on most days in the previous month (intensity >= 40mm on a visual analogue scale). Patients are randomly allocated to three groups (strontium ranelate 1 or 2 g/day, or placebo). Follow-up is expected to last 3 years. The primary endpoint is radiographic change in JSW from baseline in each group versus placebo. The main clinical secondary endpoint is WOMAC score at the knee. Safety is assessed at every visit. It is estimated that 1600 patients are required to establish statistical significance with power >90% (0.2mm +/- 10% between-group difference in change in JSW over 3 years). Recruitment started in April 2006. The results are expected in spring 2012. Clinical trial registration: The trial is registered on www.controlled-trials.com (number ISRCTN41323372). Conclusions: This randomised, double blind, placebo-controlled study will establish the potential of strontium ranelate in improving structure and symptoms in patients with knee osteoarthritis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available